Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molnupiravir: From Hope to Epic Fail?
Daniele Focosi
Viruses (2022) Vol. 14, Iss. 11, pp. 2560-2560
Open Access | Times Cited: 25

Showing 25 citing articles:

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
Daniele Focosi, Rodrigo Quiroga, Scott A. McConnell, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2264-2264
Open Access | Times Cited: 114
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 80
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 8
Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic
Philippe Colson, Hervé Chaudet, Jérémy Delerce, et al.
Journal of Infection (2024) Vol. 88, Iss. 5, pp. 106150-106150
Open Access | Times Cited: 5
Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
Yoshikazu Mutoh, Takumi Umemura, Takeshi Nishikawa, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 811-811
Open Access | Times Cited: 12
N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
Arne Zibat, Xiaoxiao Zhang, Antje Dickmanns, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107786-107786
Open Access | Times Cited: 10
Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach
Brandon Havranek, Robel Demissie, Hyun Lee, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 22, pp. 7180-7188
Open Access | Times Cited: 9
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 8
Effect of Nucleic Acid Analog Administration on Fluctuations of Albumin to Globulin Ratio in Cats with Feline Infectious Peritonitis
Masato Katayama, Yukina Uemura, Daichi Katori
(2024)
Open Access | Times Cited: 1
Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis
Huzaifa Ahmad Cheema, Saleha Abdul Rab, Momina Butt, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 3, pp. 396-402
Open Access | Times Cited: 1
Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation
Maria Nuria Peralta-Moreno, Yago Mena, David Ortega-Alarcón, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6119-6119
Open Access | Times Cited: 1
The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysis
Madison Stoddard, Yuan Lin, Sharanya Sarkar, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Acetate-encapsulated Linolenic Acid Liposomes Reduce SARS-CoV-2 and RSV Infection
Andrew R. McGill, Eleni Markoutsa, Karthick Mayilsamy, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1429-1429
Open Access | Times Cited: 4
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era
Fatima Faraz, Mohammad Ebad Ur Rehman, Abia Shahid, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1017-1019
Open Access | Times Cited: 3
Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
Yankun Liang, Lin Ma, Yuting Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Interactions between complementary medicines and drugs used in primary care and oral COVID-19 antiviral drugs
Jennifer Hunter, Joanna Harnett
Australian Journal of General Practice (2023) Vol. 52, Iss. 6, pp. 345-357
Open Access | Times Cited: 2
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
Henrik Berg Rasmussen, Peter Riis Hansen
Viruses (2023) Vol. 15, Iss. 11, pp. 2151-2151
Open Access | Times Cited: 2
Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
Daniele Focosi, Massimo Franchini, Jonathon W. Senefeld, et al.
Journal of Clinical Virology Plus (2022) Vol. 3, Iss. 1, pp. 100128-100128
Open Access | Times Cited: 4
Alterations of SARS-CoV-2 Evolutionary Dynamics by Pharmaceutical Factors
Matthew Halma
Infectious Diseases & Immunity (2024) Vol. 4, Iss. 1, pp. 35-40
Open Access
Discovery of RdRp Thumb-1 as a novel broad-spectrum antiviral family of targets and MDL-001 as a potent broad-spectrum inhibitor thereof - Part I: A Bioinformatics and Deep Learning Approach
Virgil L. Woods, Tyler Umansky, Navya Ramesh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Effect of Nucleic Acid Analog Administration on Fluctuations in the Albumin-to-Globulin Ratio in Cats with Feline Infectious Peritonitis
Masato Katayama, Yukina Uemura, Daichi Katori
Animals (2024) Vol. 14, Iss. 9, pp. 1322-1322
Open Access
Molnupiravir detection by tandem mass spectrometry
Duygu Eryavuz Onmaz, Fatma Hümryra YERLİKAYA, Mustafa Onmaz
Archives of Current Medical Research (2024) Vol. 5, Iss. 2, pp. 66-74
Open Access
Antiviral activity of Molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and implications for the therapeutic window and resistance
Tessa Prince, I’ah Donovan-Banfield, Hannah Goldswain, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 5
Dose-dependent Oxidative Damage of Molnupiravir (Antiviral Drug for Treatment of COVID-19) in Lung, Liver, Heart, and Kidney Tissues in Rats
Kevser Tanbek, Suleyman SANDAL
Archives of Pharmacology and Therapeutics (2023) Vol. 5, Iss. 1, pp. 44-52
Open Access | Times Cited: 1
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review
Massimo Franchini, Daniele Focosi
Life (2023) Vol. 13, Iss. 12, pp. 2322-2322
Open Access | Times Cited: 1
Page 1

Scroll to top